News & AnalysisTwinStrand Biosciences nabs $50m Series BTwinStrand Biosciences, a developer of duplex sequencing, has closed $50 million in Series B financing.ByIris Dorbian6 May 2021•1 min readJavaScript is required to read this article. Please enable it in your browser and reload the page.DealsHealthcareBriefs